Review article | Published 24 February 2012, doi:10.4414/smw.2012.13516
Cite this as: Swiss Med Wkly. 2012;142:w13516
Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir
Key words: boceprevir; chronic hepatitis C; HCV; hepatitis C virus; interferon; protease inhibitor; ribavirin; telaprevir
|Table 1: Definition of virological response patterns.|
|Rapid virological response (RVR)||Undetectable1 HCV RNA at week 4|
|Extended RVR (eRVR)||Undetectable HCV RNA at weeks 4 and 122|
|RVR8||Undetectable HCV RNA at week 83|
|Early virological response (EVR)||>2 log drop of HCV RNA at week 12|
|Complete EVR (cEVR)4||Undetectable HCV RNA at week 12|
|Partial EVR (pEVR)||>2 log drop but still detectable HCV RNA at week 12|
|Delayed virological response (DVR)5||>2 log drop but still detectable HCV RNA at week 12, undetectable HCV RNA at week 24|
|Partial response (PR)||>2 log drop of HCV RNA at week 12 but detectable at weeks 12 and 24|
|Null response (NR)||<2 log drop of HCV RNA at week 12|
|Breakthrough (BT)||Reappearance of HCV RNA at any time during treatment|
|Relapse||HCV RNA undetectable at end of treatment but detectable within 24 wks of follow-up|
|Sustained virological response (SVR)||Undetectable HCV RNA 24 weeks after the end of treatment|
|1 The term “undetectable” in this paper refers to HCV RNA below the limited of detection (as opposed to the limit of quantitation) of a sensitive real-time PCR assay.|
2 Relates to triple therapy comprising telaprevir.
3 Relates to triple therapy comprising boceprevir, including a 4-week lead-in phase of pegylated interferon-α and ribavirin.
4 Designated as early virological response in the recent EASL Clinical Practice Guidelines (ref. 2).
5 Formerly designated as slow virological response.
Practical use of telaprevir and boceprevir
|Table 2: Who should be treated with triple therapy comprising telaprevir (TPV) or boceprevir (BOC)?|
|CHC, chronic hepatitis C; PEG-IFN-α, pegylated interferon-α; RBV, ribavirin.|
|Table 3: Key points.|
Specific treatment algorithms
Key points are summarised in table 3.